Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Sevoflurane MAC-BAR reduction
NCT06575179Phase 4Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in cholecystectomy (3 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: Minimum alveolar concentration of sevoflurane to block the adrenergic response. Started Sep 2024; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
cholecystectomy
Beyond the preview
Go deeper on NCT06575179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575179.